CMPI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMPI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Checkmate Pharmaceuticals has the GF Value Rank of 0.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of Checkmate Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Venbio Global Strategic Fund Ii L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Alan Bash | director, officer: Chief Executive Officer | C/O CHECKMATE PAHRMACEUTICALS, INC. 245 MAIN STREET 2ND FLOOR CAMBRIDGE MA 02142 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Jon Marc Wigginton | director | 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850 |
Joy Yan | director | 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Arthur M Krieg | director, officer: Chief Scientific Officer | C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
Robert Dolski | officer: Chief Financial Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Barry Labinger | director, officer: President and CEO | C/O CHECKMATE PHARMACEUTICALS, INC., 245 MAIN STREET, 2ND FLOOR, CAMBRIDGE MA 02142 |
Peter Colabuono | director | C/O DECHENG CAPITAL 3000 SAND HILL ROAD, BUILDING 2, STE 110 MENLO PARK CA 94025 |
Oren Isacoff | director | C/O LONGITUDE CAPITAL 2740 SAND HILL ROAD, 2ND FLOOR MENLO PARK CA 94025 |
Karen Brennan | officer: Chief Operating Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Kleem Chaudhary | officer: Chief Business Officer | C/O CHECKMATE PHARMACEUTICALS, INC. 245 MAIN STREET, 2ND FLOOR CAMBRIDGE MA 02142 |
Venbio Global Strategic Gp Ii, L.p. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Venbio Global Strategic Gp Ii, Ltd. | 10 percent owner | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Nilesh Kumar | director | C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6 |
From GuruFocus
By PRNewswire PRNewswire • 05-26-2022
By PRNewswire PRNewswire • 06-06-2022
By GuruFocusNews GuruFocusNews • 06-01-2022
By GuruFocusNews GuruFocusNews • 05-12-2022
By PRNewswire PRNewswire • 06-15-2022
By PRNewswire PRNewswire • 05-17-2022
By PRNewswire PRNewswire • 06-25-2022
By PRNewswire PRNewswire • 04-19-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.